Trial Profile
A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 24 Aug 2021 Status changed from active, no longer recruiting to completed.
- 25 Mar 2021 Results assessing (n=48; Cohort 1; between 2 Apr 2018 and 13 Nov 2018; cutoff date 29 Feb, 2020) efficacy and safety of camrelizumab in combination with CAPOX followed by camrelizumab plus apatinib as first-line combination regimen for advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, published in the Clinical Cancer Research.
- 28 Apr 2020 Planned End Date changed from 30 Dec 2019 to 30 Dec 2020.